trial · primary record
Adalimumab
Uveitis
| Phase | Phase 2 |
|---|---|
| Status | TERMINATED |
| Sponsor | Unknown |
| Enrolment | 23 |
| Primary completion | 2022-01 |
| Primary endpoint | Vitreous Haze |
| Registry ID | NCT02706704 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:44:10.968Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT02706704
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Adalimumab · approval
- Adalimumab · compound